Cargando…

Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer

In epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), acquired resistance to EGFR tyrosine kinase inhibitors (TKI) leads to disease progression. Strategies to overcome the resistance are required in treatment for advanced lung cancer. In this study, we investigated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Si Yeon, Park, Ji Hye, Park, So-Jung, Kang, In-Cheol, Yoo, Hwa-Seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793066/ https://www.ncbi.nlm.nih.gov/pubmed/36565160 http://dx.doi.org/10.1177/15347354221144311

Ejemplares similares

Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice
por: Kang, Hwa Jeong, et al.
Publicado: (2019)

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
por: Song, Si-Yeon, et al.
Publicado: (2020)

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
por: Chen, Gang, et al.
Publicado: (2013)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells
por: Wang, Miao, et al.
Publicado: (2018)

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy
por: Ko, Eun-Ju, et al.
Publicado: (2021)

Acute and Subchronic Toxicological Evaluation of the Herbal Product HAD-B1 in Rats
por: Park, So-Jung, et al.
Publicado: (2021)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Nonclinical Safety Pharmacology Study of the Herbal Product HAD-B1
por: Kim, Soo-Dam, et al.
Publicado: (2021)

Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy: Study protocol clinical trial (SPIRIT Compliant)
por: Park, So-Jung, et al.
Publicado: (2020)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs
por: Song, Si-Yeon, et al.
Publicado: (2021)

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
por: Fujiwara, Atsushi, et al.
Publicado: (2018)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
por: SUTANDYO, Noorwati, et al.
Publicado: (2019)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
por: Yoon, Byung Woo, et al.
Publicado: (2019)

EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
por: You, Joyce H. S., et al.
Publicado: (2021)

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
por: Paz-Ares, L., et al.
Publicado: (2017)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
por: Schuler, Martin, et al.
Publicado: (2019)

Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib
por: Park, Sejeong, et al.
Publicado: (2018)

Drug-Like Small Molecule HSP27 Functional Inhibitor Sensitizes Lung Cancer Cells to Gefitinib or Cisplatin by Inducing Altered Cross-Linked Hsp27 Dimers
por: Yoo, Hawon, et al.
Publicado: (2021)

Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report
por: Lee, Su Jin, et al.
Publicado: (2012)

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
por: Bae, Song Yi, et al.
Publicado: (2015)

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
por: Stoppoloni, Daniela, et al.
Publicado: (2010)

Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
por: Park, Cheol Kyu, et al.
Publicado: (2017)

Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer
por: Lee, Kangwook, et al.
Publicado: (2016)

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
por: Park, Soo-Yeon, et al.
Publicado: (2010)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
por: Kwok, Wang Chun, et al.
Publicado: (2022)

Transformation to small cell lung cancer after first-line afatinib treatment
por: Shiroyama, Takayuki, et al.
Publicado: (2018)

An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib
por: Kwon, Taeho, et al.
Publicado: (2015)

Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
por: Brzozowska, Melania, et al.
Publicado: (2019)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
por: Cho, Jung Hee, et al.
Publicado: (2022)

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2017)

Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions
por: Bae, Song Yi, et al.
Publicado: (2016)

Correction: GPR119 agonist enhances gefitinib responsiveness through lactate-mediatedinhibition of autophagy
por: Im, Ji Hye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h22rjatn6r57271fm7keeeie93